Total Payments
$114,845
2024 Payments
$3,729
Companies
76
Transactions
2,451
Medicare Patients
8,098
Medicare Billing
$1.7M
Payment Breakdown by Category
Other$57,735 (50.3%)
Food & Beverage$33,265 (29.0%)
Consulting$17,879 (15.6%)
Travel$5,919 (5.2%)
Education$46.94 (0.0%)
Gifts$0.04 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,010 | 22 | 39.2% |
| Food and Beverage | $33,265 | 2,381 | 29.0% |
| Consulting Fee | $17,879 | 7 | 15.6% |
| Honoraria | $9,125 | 7 | 7.9% |
| Travel and Lodging | $5,919 | 15 | 5.2% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,600 | 3 | 3.1% |
| Education | $46.94 | 12 | 0.0% |
| Gift | $0.04 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| INSYS Therapeutics Inc | $22,835 | 17 | $0 (2018) |
| Pernix Therapeutics Holdings, Inc. | $21,129 | 52 | $0 (2019) |
| Collegium Pharmaceutical, Inc. | $11,727 | 222 | $0 (2024) |
| West Therapeutics Development, LLC | $8,702 | 14 | $0 (2019) |
| US WorldMeds, LLC | $7,238 | 44 | $0 (2020) |
| BioDelivery Sciences International, Inc. | $7,153 | 156 | $0 (2021) |
| AKRIMAX PHARMACEUTICALS, LLC | $4,611 | 49 | $0 (2018) |
| Arbor Pharmaceuticals, Inc. | $4,379 | 126 | $0 (2022) |
| ABBVIE INC. | $2,361 | 137 | $0 (2024) |
| Daiichi Sankyo Inc. | $1,989 | 193 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,729 | 251 | Collegium Pharmaceutical, Inc. ($835.27) |
| 2023 | $3,776 | 249 | AbbVie Inc. ($862.76) |
| 2022 | $3,155 | 208 | ABBVIE INC. ($385.30) |
| 2021 | $7,761 | 355 | Regeneron Pharmaceuticals, Inc. ($1,860) |
| 2020 | $3,890 | 247 | BIODELIVERY SCIENCES INTERNATIONAL, INC. ($1,110) |
| 2019 | $15,396 | 323 | US WorldMeds, LLC ($7,072) |
| 2018 | $26,094 | 405 | Pernix Therapeutics Holdings, Inc. ($5,984) |
| 2017 | $51,043 | 413 | INSYS Therapeutics Inc ($18,323) |
All Payment Transactions
2,451 individual payment records from CMS Open Payments — Page 1 of 99
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $19.89 | General |
| Category: Opioid Analgesic | ||||||
| 12/19/2024 | Valinor Pharma, LLC | MOVANTIK (Drug) | Food and Beverage | In-kind items and services | $7.96 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: Analgesic | ||||||
| 12/18/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $2.89 | General |
| Category: Analgesic | ||||||
| 12/16/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $17.42 | General |
| Category: Opioid Analgesic | ||||||
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | Valinor Pharma, LLC | MOVANTIK (Drug) | Food and Beverage | In-kind items and services | $8.75 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $30.29 | General |
| Category: NEUROSCIENCE | ||||||
| 12/09/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $17.65 | General |
| Category: Opioid Analgesic | ||||||
| 12/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: PAIN | ||||||
| 12/04/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: PAIN | ||||||
| 12/04/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Analgesic | ||||||
| 12/03/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $8.12 | General |
| Category: Opioid Analgesic | ||||||
| 12/03/2024 | Valinor Pharma, LLC | MOVANTIK (Drug) | Food and Beverage | In-kind items and services | $6.27 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $21.10 | General |
| Category: Addiction Medicine | ||||||
| 12/02/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $17.52 | General |
| Category: Opioid Analgesic | ||||||
| 11/27/2024 | Valinor Pharma, LLC | MOVANTIK (Drug) | Food and Beverage | In-kind items and services | $8.95 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/26/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $35.29 | General |
| 11/25/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $19.62 | General |
| Category: Opioid Analgesic | ||||||
| 11/25/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: Gastroenterology | ||||||
| 11/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Analgesic | ||||||
| 11/20/2024 | Valinor Pharma, LLC | MOVANTIK (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $1.81 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | TerSera Therapeutics LLC | Prialt (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Pain Management | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 2,789 | 7,647 | $1.9M | $584,511 |
| 2022 | 21 | 1,919 | 5,770 | $1.4M | $423,648 |
| 2021 | 17 | 1,756 | 4,982 | $1.1M | $354,109 |
| 2020 | 16 | 1,634 | 4,766 | $990,622 | $310,044 |
Total Patients
8,098
Total Services
23,165
Medicare Billing
$1.7M
Procedure Codes
80
All Medicare Procedures & Services
80 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 462 | 2,350 | $254,275 | $179,977 | 70.8% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 329 | 667 | $600,300 | $102,358 | 17.1% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 211 | 383 | $497,900 | $92,678 | 18.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 350 | 707 | $70,700 | $43,056 | 60.9% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2023 | 98 | 179 | $89,500 | $41,937 | 46.9% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 439 | 1,861 | $46,525 | $22,911 | 49.2% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 59 | 94 | $108,100 | $18,308 | 16.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 90 | 90 | $17,803 | $13,286 | 74.6% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2023 | 33 | 50 | $15,301 | $11,387 | 74.4% |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | Office | 2023 | 27 | 41 | $20,500 | $10,177 | 49.6% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 16 | 25 | $13,465 | $10,142 | 75.3% |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | Office | 2023 | 30 | 69 | $9,534 | $7,389 | 77.5% |
| 76942 | Ultrasonic guidance for needle placement | Office | 2023 | 66 | 138 | $9,641 | $7,065 | 73.3% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 15 | 25 | $7,409 | $5,796 | 78.2% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 36 | 80 | $6,005 | $4,405 | 73.4% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 44 | 59 | $3,812 | $2,754 | 72.2% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 19 | 25 | $3,750 | $2,249 | 60.0% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 118 | 221 | $24,973 | $2,058 | 8.2% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 128 | 253 | $26,312 | $1,482 | 5.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 11 | $1,660 | $1,182 | 71.2% |
| 77002 | Fluoroscopic guidance for needle placement | Office | 2023 | 13 | 14 | $1,300 | $1,019 | 78.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 18 | 19 | $1,520 | $972.88 | 64.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 18 | $1,218 | $928.23 | 76.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 13 | 14 | $1,114 | $810.68 | 72.8% |
| J1020 | Injection, methylprednisolone acetate, 20 mg | Office | 2023 | 32 | 33 | $3,333 | $157.03 | 4.7% |
About Dr. Alexander Weingarten, MD
Dr. Alexander Weingarten, MD is a Interventional Pain Medicine healthcare provider based in Syosset, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1558353078.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexander Weingarten, MD has received a total of $114,845 in payments from pharmaceutical and medical device companies, with $3,729 received in 2024. These payments were reported across 2,451 transactions from 76 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($45,010).
As a Medicare-enrolled provider, Weingarten has provided services to 8,098 Medicare beneficiaries, totaling 23,165 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 80 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Pain Medicine
- Location Syosset, NY
- Active Since 08/19/2005
- Last Updated 03/13/2008
- Taxonomy Code 208VP0014X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1558353078
Products in Payments
- SUBSYS (Drug) $22,835
- ZOHYDRO ER (Drug) $21,096
- Xtampza ER (Drug) $9,115
- Lazanda (Drug) $8,702
- Lucemyra/Lofexidine (Drug) $7,146
- BELBUCA (Drug) $6,754
- Horizant (Drug) $4,307
- PRIMLEV (Drug) $3,600
- NURTEC ODT (Drug) $2,148
- XTAMPZA (Drug) $1,971
- UBRELVY (Drug) $1,541
- ZTLido (Drug) $1,452
- Morphabond ER (Drug) $1,427
- Movantik (Drug) $1,373
- TRINTELLIX (Drug) $804.79
- QULIPTA (Drug) $775.00
- Trintellix (Drug) $731.95
- MOVANTIK (Drug) $731.08
- Prialt (Drug) $663.37
- SEGLENTIS (Drug) $661.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.